Imaging in thoracic oncology: case studies from Multidisciplinary Thoracic Tumor Board (part 1 of 2 part series)

Our plain-English summary of Imaging in thoracic oncology: case studies from Multidisciplinary Thoracic Tumor Board (part 1 of 2 part series), by L.E. Quint, R.M. Reddy, J. Lin, et al (Cancer Imaging, 2013).

The study

• Authors: L.E. Quint, R.M. Reddy, J. Lin, D.A. Arenberg, C. Speers, J.A. Hayman, F.P. Kong, M.B. Orringer, G.P. Kalemkerian
• Journal: Cancer Imaging
• Published: 2013;13(3):429-39
• Type of article: Case report
• Cited by: 2 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Multidisciplinary tumor board conferences foster collaboration among health care providers from a variety of specialties and help to facilitate optimal patient care. Typical cases from thoracic tumor board conferences include patients with known or suspected bronchogenic and esophageal carcinomas, as well as less common diseases such as thymomas and mesotheliomas. In most instances, the clinical questions revolve around the best options for establishing a diagnosis, staging the disease and directing treatment. This article describes and illustrates the clinical scenarios of three patients who were presented at our tumor board, focusing on management issues and the role of imaging. These patients had non-small cell lung cancer and mediastinal lymph node metastases; a small, growing ground glass nodule; and oligometastatic non-small cell lung cancer, respectively.

In plain English

This article was a case series from the weekly Thoracic Tumor Board at the University of Michigan Medical Center. It described three patients with lung cancer and how imaging shaped their care. It did not study asbestos. Mesothelioma was mentioned only as one of the less common diseases discussed at such conferences. In the first case, a 52-year-old man with a right upper lobe lung mass had mediastinoscopy. It found metastatic adenocarcinoma in a subcarinal lymph node, consistent with stage IIIA lung cancer, and surgery was postponed until after chemoradiotherapy. In the second case, a 70-year-old woman's ground glass nodule grew from 4 mm to about 9 mm even though a needle biopsy showed no cancer. After it was marked with dye and coils, it was removed and found to be a 9-mm bronchioloalveolar adenocarcinoma. In the third case, a 53-year-old woman with a lung cancer metastasis in the kidney had new lung nodules that resolved on repeat CT. After her kidney was removed, scans showed no evidence of recurrent or metastatic disease. The authors concluded that imaging may be inconclusive or misleading and must be interpreted in clinical context.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: case series (three patient case descriptions with discussion of management)
• Who was studied: Three patients presented at the Thoracic Tumor Board of the University of Michigan Medical Center, Ann Arbor, USA: a 52-year-old man, a 70-year-old woman and a 53-year-old woman, with case events between 2003 and 2012. This is Part 1 of a two-part series.
• Exposure: No asbestos exposure was described. The article is about imaging and management of lung cancer. The only exposure history reported was a 40 pack-year smoking history in the first patient.
• Main results:
  • Case 1 (52-year-old man): a subcarinal lymph node sampled at mediastinoscopy showed metastatic poorly differentiated adenocarcinoma consistent with stage IIIA lung cancer. Further surgery was postponed until after neoadjuvant chemoradiotherapy.
  • Case 2 (70-year-old woman): a left lower lobe ground glass nodule grew from 4 mm (May 2006) to about 9 mm (November 2008). A CT-guided needle biopsy had been false-negative. After localization with electromagnetic navigational bronchoscopy, dye and coils, wedge resection showed a 9-mm bronchioloalveolar adenocarcinoma with tumor-free margins.
  • Case 3 (53-year-old woman): new lung nodules seen in January 2012 were judged by the Tumor Board more likely to be infection. They resolved completely on repeat CT in February 2012.
  • Case 3: after a right radical nephrectomy for the metastatic adenocarcinoma in the kidney, follow-up CT scans of the chest and abdomen in June 2012 showed no evidence of recurrent or metastatic disease.
• The authors' conclusion: The authors concluded that imaging plays a role in guiding the care of thoracic oncology patients but may be inconclusive or occasionally misleading and must be interpreted in light of the clinical context. They also concluded that input from the whole multidisciplinary tumor board helps integrate imaging findings into patient care.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer.

Medical terms in this study, explained in our Lexicon: Tumor Board, Benjamin Foster Company, Bronchogenic Carcinoma, Carcinoma, Mesothelioma, Staging, Non-Small Cell Lung Cancer.

Related studies

• New applications of magnetic resonance imaging for thoracic oncology — Y. Ohno (2014)
• Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors — S. Hendry, R. Salgado, et al. (2017)
• Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial--an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002) — G. Fasola, O. Belvedere, et al. (2007)
• Recognition of and treatment recommendations for oligometastatic disease in multidisciplinary tumor boards — S.M. Christ, P. Heesen, et al. (2023)
• Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC — F. Facchinetti, A. Marabelle, et al. (2016)
• Differential sensitivity of thoracic malignant tumors to adenovirus-mediated drug sensitization gene therapy — W.R. Smythe, H.C. Hwang, et al. (1995)

Browse more research in Cancer Imaging, or return to medical research.